{"id":1056,"date":"2024-06-04T13:30:45","date_gmt":"2024-06-04T13:30:45","guid":{"rendered":"https:\/\/www.arcgroup.io\/uxbridge\/?p=1056"},"modified":"2024-06-04T13:30:47","modified_gmt":"2024-06-04T13:30:47","slug":"amgen-new-medicine","status":"publish","type":"post","link":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/","title":{"rendered":"Amgen secures first fast paced approval for life-saving new medicine"},"content":{"rendered":"\n<!-- Back button -->\n<div class=\"back-button-block__container\">\n\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/community\/\" class=\"back-button-block\">\n\t\t<svg class=\"back-button-block__arrow\" width=\"13\" height=\"13\">\n\t\t\t<use xlink:href=\"#small-arrow\"><\/use>\n\t\t<\/svg>\n\t\tBack to Community\t<\/a>\n<\/div>\n\n\n\n<section class=\"feature-banner\" id=\"block_b640d60e9cf17727d25458be911283a4\"> \n    <div class=\"feature-banner__container\">\n            <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/06\/uk-secondary1.jpg 850w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/06\/uk-secondary1-300x124.jpg 300w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/06\/uk-secondary1-768x317.jpg 768w\" type=\"image\/jpeg\" sizes=\"(max-width: 768px) 768px, (max-width: 1024px) 1024px, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/06\/uk-secondary1.jpg\" \/>\n            <\/picture>\n\n    <\/div>\n<\/section>\n\n\n<h2 class=\"wp-block-post-title\">Amgen secures first fast paced approval for life-saving new medicine<\/h2>\n\n\n    <ul class=\"ed-post-categories\">\n                    <li class=\"arc-purple\">\n                <a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/category\/corporate\/\">Corporate<\/a>\n            <\/li>\n                    <li class=\"arc-orange\">\n                <a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/category\/news\/\">News<\/a>\n            <\/li>\n            <\/ul>\n\n\n\n<p>Amgen, based at ARC Uxbridge, has secured the first approval via the new International Recognition Procedure which aims to further help bring life-saving new medicines to UK patients without delay.<\/p>\n\n\n\n<p>A new formulation for XGEVA (denosumab), a treatment used in adults to prevent serious bone-related complications caused by bone metastasis and to treat giant cell tumour of bone in adults and adolescents, is the first product to be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).<\/p>\n\n\n\n<p>The IRP allows the MHRA to accelerate the assessment of new medicines by taking into account the expertise and decision-making of trusted regulatory partners in the authorisation process. As a result, medicines that have been approved in other countries with stringent regulators will get to UK patients without delay, resulting in a more rapid, efficient, and cost-effective process for life sciences companies.<\/p>\n\n\n\n<p>Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access, said:<\/p>\n\n\n\n<p>\u201cWe are focused on providing UK patients rapid access to safe and effective medical treatments. I\u2019m very pleased to announce that we have granted the first approval through IRP in 30 days, demonstrating that this new process for bringing new medicines to UK patients is well under way. We\u2019re assured that the appropriate regulatory standards for the approval of this medicine have been met. As with all products, we will keep its safety under close review.\u201d<\/p>\n\n\n\n<p>Health Minister Andrew Stephenson said: \u201cNHS patients should have access to the newest, most effective medicines and treatments without delay. This new international agreement allows treatments to be approved more quickly by drawing on expertise from partners across the world, reducing bureaucracy and sharing resources so patients can benefit as soon as possible. XGEVA being approved quicker than usual is testament to this innovative approach.\u201d<\/p>\n\n\n\n<p>You can read the full release <a href=\"https:\/\/www.gov.uk\/government\/news\/mhra-grants-first-approval-via-the-new-international-recognition-procedure-in-30-days\">here<\/a><\/p>\n\n\n\n<p>ARC Uxbridge has a growing biotech and pharmaceutical cluster including join biotech and including, Bristol Myers Squibb, Parexel and Daiichi Sankyo.<\/p>\n\n\n    <section class=\"news-archive \" id=\"block_f22c2591c39be794a9a1637acb7347a9\">\n                    <div class=\"ed-container news-archive__title ed-archive-header__title ed-archive-header__title--large\">\n                <div class=\"ed-row\">\n                    <div class=\"ed-col ed-col__half\">\n                        \n                            <h3>More News<\/h3>\n                                            <\/div>\n                    <div class=\"ed-col ed-col__half\">\n                                                    <a href=\"https:\/\/www.arcgroup.io\/uxbridge\/community\/\" target=\"\">\n                                View all news &rarr;\n                            <\/a>\n                                            <\/div>\n                <\/div>\n            <\/div>\n                <div class=\"ed-container\">\n            <div class=\"ed-row\">\n                \n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-scaled.jpg 2560w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-300x207.jpg 300w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-1024x706.jpg 1024w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-768x530.jpg 768w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-1000x690.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-scaled.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/\" target=\"_self\">\n\t\t\t\tAmgen acquires Dark Blue Therapeutics, bolstering oncology pipeline\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2025\/07\/11\/arc-uxbridge-named-workspace-of-the-year-at-the-2025-hustle-awards\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter.jpg 2560w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter-300x200.jpg 300w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter-1024x683.jpg 1024w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter-768x512.jpg 768w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter-1000x667.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2025\/07\/11\/arc-uxbridge-named-workspace-of-the-year-at-the-2025-hustle-awards\/\" target=\"_self\">\n\t\t\t\tARC Uxbridge, named Workspace of the Year at the 2025 Hustle Awards\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2025\/03\/25\/arc-uxbridge-outperforms-5-year-average-uptake-for-the-area\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-scaled.jpg 2560w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-300x200.jpg 300w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-1024x682.jpg 1024w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-768x512.jpg 768w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-1000x666.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-scaled.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2025\/03\/25\/arc-uxbridge-outperforms-5-year-average-uptake-for-the-area\/\" target=\"_self\">\n\t\t\t\tBrookfield&#8217;s ARC Uxbridge Campus Outperforms 5-year average uptake for the area following surge in high-profile leases\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n            <\/div>\n        <\/div>\n    <\/section>\n","protected":false},"excerpt":{"rendered":"<p>Amgen, based at ARC Uxbridge, has secured the first approval via the new International Recognition Procedure which aims to further help bring life-saving new medicines to UK patients without delay. A new formulation for XGEVA (denosumab), a treatment used in adults to prevent serious bone-related complications caused by bone metastasis and to treat giant cell [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":1057,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[30,22],"tags":[],"class_list":["post-1056","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-corporate","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Amgen secures first fast paced approval for life-saving new medicine - ARC Uxbridge<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen secures first fast paced approval for life-saving new medicine - ARC Uxbridge\" \/>\n<meta property=\"og:description\" content=\"Amgen, based at ARC Uxbridge, has secured the first approval via the new International Recognition Procedure which aims to further help bring life-saving new medicines to UK patients without delay. A new formulation for XGEVA (denosumab), a treatment used in adults to prevent serious bone-related complications caused by bone metastasis and to treat giant cell [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"ARC Uxbridge\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-04T13:30:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-04T13:30:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/06\/uk-secondary1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"850\" \/>\n\t<meta property=\"og:image:height\" content=\"351\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"rebeccabethwaite\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"rebeccabethwaite\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/\"},\"author\":{\"name\":\"rebeccabethwaite\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57\"},\"headline\":\"Amgen secures first fast paced approval for life-saving new medicine\",\"datePublished\":\"2024-06-04T13:30:45+00:00\",\"dateModified\":\"2024-06-04T13:30:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/\"},\"wordCount\":331,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/06\/uk-secondary1.jpg\",\"articleSection\":[\"Corporate\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/\",\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/\",\"name\":\"Amgen secures first fast paced approval for life-saving new medicine - ARC Uxbridge\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/06\/uk-secondary1.jpg\",\"datePublished\":\"2024-06-04T13:30:45+00:00\",\"dateModified\":\"2024-06-04T13:30:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/#primaryimage\",\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/06\/uk-secondary1.jpg\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/06\/uk-secondary1.jpg\",\"width\":850,\"height\":351,\"caption\":\"Amgen ARC Uxbridge\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.arcgroup.io\/uxbridge\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amgen secures first fast paced approval for life-saving new medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#website\",\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/\",\"name\":\"ARC Uxbridge\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#organization\"},\"alternateName\":\"ARC Uxbridge\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.arcgroup.io\/uxbridge\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#organization\",\"name\":\"ARC Uxbridge\",\"alternateName\":\"ARC Uxbridge\",\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/06\/ARC-SUBBRANDS-LOGOS-03-UXBRIDGE-1.png\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/06\/ARC-SUBBRANDS-LOGOS-03-UXBRIDGE-1.png\",\"width\":2084,\"height\":2085,\"caption\":\"ARC Uxbridge\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57\",\"name\":\"rebeccabethwaite\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g\",\"caption\":\"rebeccabethwaite\"},\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/author\/rebeccafrost\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amgen secures first fast paced approval for life-saving new medicine - ARC Uxbridge","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/","og_locale":"en_US","og_type":"article","og_title":"Amgen secures first fast paced approval for life-saving new medicine - ARC Uxbridge","og_description":"Amgen, based at ARC Uxbridge, has secured the first approval via the new International Recognition Procedure which aims to further help bring life-saving new medicines to UK patients without delay. A new formulation for XGEVA (denosumab), a treatment used in adults to prevent serious bone-related complications caused by bone metastasis and to treat giant cell [&hellip;]","og_url":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/","og_site_name":"ARC Uxbridge","article_published_time":"2024-06-04T13:30:45+00:00","article_modified_time":"2024-06-04T13:30:47+00:00","og_image":[{"width":850,"height":351,"url":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/06\/uk-secondary1.jpg","type":"image\/jpeg"}],"author":"rebeccabethwaite","twitter_card":"summary_large_image","twitter_misc":{"Written by":"rebeccabethwaite","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/#article","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/"},"author":{"name":"rebeccabethwaite","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57"},"headline":"Amgen secures first fast paced approval for life-saving new medicine","datePublished":"2024-06-04T13:30:45+00:00","dateModified":"2024-06-04T13:30:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/"},"wordCount":331,"commentCount":0,"publisher":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/#organization"},"image":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/06\/uk-secondary1.jpg","articleSection":["Corporate","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/","url":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/","name":"Amgen secures first fast paced approval for life-saving new medicine - ARC Uxbridge","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/#primaryimage"},"image":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/06\/uk-secondary1.jpg","datePublished":"2024-06-04T13:30:45+00:00","dateModified":"2024-06-04T13:30:47+00:00","breadcrumb":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/#primaryimage","url":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/06\/uk-secondary1.jpg","contentUrl":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/06\/uk-secondary1.jpg","width":850,"height":351,"caption":"Amgen ARC Uxbridge"},{"@type":"BreadcrumbList","@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/06\/04\/amgen-new-medicine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.arcgroup.io\/uxbridge\/"},{"@type":"ListItem","position":2,"name":"Amgen secures first fast paced approval for life-saving new medicine"}]},{"@type":"WebSite","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#website","url":"https:\/\/www.arcgroup.io\/uxbridge\/","name":"ARC Uxbridge","description":"","publisher":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/#organization"},"alternateName":"ARC Uxbridge","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arcgroup.io\/uxbridge\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#organization","name":"ARC Uxbridge","alternateName":"ARC Uxbridge","url":"https:\/\/www.arcgroup.io\/uxbridge\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/logo\/image\/","url":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/06\/ARC-SUBBRANDS-LOGOS-03-UXBRIDGE-1.png","contentUrl":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/06\/ARC-SUBBRANDS-LOGOS-03-UXBRIDGE-1.png","width":2084,"height":2085,"caption":"ARC Uxbridge"},"image":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57","name":"rebeccabethwaite","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g","caption":"rebeccabethwaite"},"url":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/author\/rebeccafrost\/"}]}},"_links":{"self":[{"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/posts\/1056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/comments?post=1056"}],"version-history":[{"count":0,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/posts\/1056\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/media\/1057"}],"wp:attachment":[{"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/media?parent=1056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/categories?post=1056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/tags?post=1056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}